Live price temporarily unavailable.
Price history
Arcadia Biosciences (RKDA) is a Energy company. Latest news and coverage below.
IPO: May 15, 2015 · $8.00 offering · NASDAQ · View IPO details →
Arcadia Biosciences revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.19M | $4.03M | $1.46M | $1.17M | $8.03M | $6.78M | $7.42M | $4.45M | $5.04M | $4.86M |
| Growth (year over year) | −41.1% | +26.3% | −63.6% | −20.2% | +587.3% | −15.6% | +9.4% | −40.0% | +13.3% | −3.7% |
| Gross profit | $2.29M | $3.74M | — | — | $2.83M | −$1.93M | $1.32M | $2.28M | $2.08M | $1.76M |
| Gross margin | 71.9% | 93.0% | — | — | 35.3% | −28.4% | 17.8% | 51.2% | 41.3% | 36.2% |
| Operating income | −$18.6M | −$14.3M | −$16.9M | −$19.4M | −$12.8M | −$35.5M | −$14.0M | −$6.10M | −$3.65M | −$2.50M |
| Operating margin | −584.1% | −355.6% | −1152.3% | −1657.9% | −159.0% | −524.0% | −188.8% | −137.0% | −72.3% | −51.5% |
| Net income | −$19.6M | −$15.7M | −$13.5M | −$28.8M | −$4.66M | −$14.7M | −$15.4M | −$14.0M | −$7.04M | −$2.34M |
| Net margin | −615.6% | −390.1% | −920.8% | −2464.1% | −57.9% | −216.2% | −207.3% | −313.9% | −139.5% | −48.1% |
| EPS (diluted) | −$14160.00 | −$11648.00 | −$5728.00 | −$7248.00 | −$752.00 | −$1102.40 | −$1026.00 | −$11.29 | −$5.17 | −$1.71 |
| Balance sheet | ||||||||||
| Cash and equivalents | $2.01M | $9.13M | $12.0M | $8.42M | $14.0M | $28.7M | $20.6M | $6.52M | $4.24M | $259.0K |
| Total assets | $56.6M | $16.6M | $24.0M | $32.6M | $47.3M | $43.9M | $28.9M | $19.7M | $13.5M | $6.55M |
| Total liabilities | $34.4M | $8.56M | $11.2M | $24.2M | $18.8M | $12.7M | $8.02M | $7.00M | $7.29M | $2.41M |
| Long-term debt | $25.1M | $0 | $0 | $107.0K | $2.10M | $0 | — | — | — | — |
| Shareholders' equity | $22.2M | $8.01M | $12.8M | $7.71M | $27.7M | $31.1M | $21.0M | $12.8M | $6.22M | $4.14M |
| Cash flow | ||||||||||
| Operating cash flow | −$17.1M | −$14.0M | −$13.6M | −$17.2M | −$30.2M | −$25.9M | −$14.0M | −$15.3M | −$9.63M | −$4.74M |
| Capital expenditure | $231.0K | $79.0K | $250.0K | $1.48M | $2.33M | $1.01M | $72.0K | $5.00K | $16.0K | $0 |
| Free cash flow | −$17.3M | −$14.0M | −$13.9M | −$18.7M | −$32.6M | −$26.9M | −$14.0M | −$15.3M | −$9.64M | −$4.74M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.54M | $1.22M | $1.20M | $1.46M | $1.30M | $901.0K | $1.10M | $1.44M |
| Growth (year over year) | +18.4% | +93.8% | +21.6% | +11.4% | −15.3% | −25.8% | −8.3% | −0.8% |
| Gross profit | $505.0K | $388.0K | $518.0K | $631.0K | $418.0K | $193.0K | $400.0K | $631.0K |
| Gross margin | 32.9% | 31.9% | 43.2% | 43.4% | 32.1% | 21.4% | 36.4% | 43.7% |
| Operating income | −$1.76M | −$2.28M | $530.0K | −$501.0K | −$1.15M | −$1.38M | −$779.0K | −$496.0K |
| Operating margin | −114.5% | −187.7% | 44.2% | −34.4% | −88.5% | −152.8% | −70.8% | −34.4% |
| Net income | −$1.61M | −$4.06M | $2.60M | −$4.46M | $856.0K | −$1.34M | −$4.38M | −$6.27M |
| Net margin | −104.9% | −334.5% | 216.6% | −306.4% | 65.7% | −148.3% | −398.6% | −434.2% |
| EPS (diluted) | −$1.18 | −$2.99 | $1.90 | −$3.26 | $0.62 | −$0.97 | −$2.11 | −$2.09 |
| Balance sheet | ||||||||
| Cash and equivalents | $3.94M | $4.24M | $3.16M | $1.38M | $1.12M | $259.0K | $954.0K | $4.18M |
| Total assets | $15.2M | $13.5M | $13.0M | $7.79M | $8.58M | $6.55M | $5.32M | $5.89M |
| Total liabilities | $5.09M | $7.29M | $4.08M | $3.25M | $3.14M | $2.41M | $2.44M | $5.26M |
| Shareholders' equity | $10.3M | $6.22M | $8.90M | $4.53M | $5.44M | $4.14M | $2.88M | $633.0K |
| Cash flow | ||||||||
| Operating cash flow | −$1.75M | −$2.21M | −$1.59M | −$2.03M | −$257.0K | −$861.0K | −$1.10M | −$319.0K |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Free cash flow | −$1.75M | −$2.21M | −$1.59M | −$2.03M | −$257.0K | −$861.0K | — | — |
From Arcadia Biosciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Arcadia Biosciences
Arcadia Biosciences is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation.
Source: Wikipedia — Arcadia Biosciences
- Headquarters
- Dallas, Texas From SEC filings, Oct 2026
Recent News
No recent news mentioning Arcadia Biosciences in our feed yet.
More Energy stocks
- APA APA Corporation
- BKR Baker Hughes
- COP ConocoPhillips
- CVX Chevron Corporation
- DVN Devon Energy
- EOG EOG Resources
- EQT EQT Corporation
- EXE Expand Energy